Emergent Biosolutions
EBS
353 hedge funds and large institutions have $3.96B invested in Emergent Biosolutions in 2020 Q4 according to their latest regulatory filings, with 59 funds opening new positions, 154 increasing their positions, 110 reducing their positions, and 61 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 154 | Existing positions reduced: 110
1.89% more ownership
Funds ownership: 81.65% → 83.54% (+1.9%)
1% more call options, than puts
Call options by funds: $18.6M | Put options by funds: $18.4M
3% less first-time investments, than exits
New positions opened: 59 | Existing positions closed: 61
1% less funds holding
Funds holding: 358 → 353 (-5)
11% less capital invested
Capital invested by funds: $4.45B → $3.96B (-$494M)
67% less funds holding in top 10
Funds holding in top 10: 6 → 2 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$86.6M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$38.1M |
| 3 |
VNIM
Vaughan Nelson Investment Management
Houston,
Texas
|
+$35.7M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$34.1M |
| 5 |
State Street
Boston,
Massachusetts
|
+$26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$64.8M |
| 2 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$36.4M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$35.3M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$31.9M |
| 5 |
Two Sigma Investments
New York
|
-$28.7M |
EBS Hedge Fund Activity: Q4 2020 in Review
353 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q4 2020, worth a combined $3.96B — down 11% from $4.45B a quarter earlier.
Sellers outnumbered buyers: 61 funds closed out of EBS and 59 opened new positions — a net loss of 2 holders — while 110 trimmed existing stakes and 154 added.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $86.6M. The largest seller was 1832 Asset Management, exiting entirely with an estimated $64.8M sold.
- 353 institutional investors held Emergent Biosolutions (EBS) as of Q4 2020, down from 358 in Q3 2020.
- Funds reported $3.96B of Emergent Biosolutions stock for Q4 2020, down 11% quarter-over-quarter.
- 59 funds opened new Emergent Biosolutions positions in Q4 2020 and 61 closed out, a net change of -2 holders.
- The largest Emergent Biosolutions buyer in Q4 2020 was Janus Henderson Group, an estimated $86.6M added.
- The largest Emergent Biosolutions seller in Q4 2020 was 1832 Asset Management, an estimated $64.8M sold.
Based on aggregated 13F filings for Q4 2020.